Clck to enlarge and view details
US PROVISIONAL PATENT APPLICATIONS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED IN 2013
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included drugs, medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors,
heparin, warfarin and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly
relevant documents.

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US PATENT APPLICATIONS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2013



Application No.: US20130001165A1  Published: 03/Jan/2013

Title: SYSTEM FOR CARRYING OUT A BLOOD TREATMENT

Applicant/Assignee:

Application No.: 13/634355   Filing Date: 14/Mar/2011

Abstract:

The present invention relates to a system for the carrying out of a blood treatment, in particular a dialysis treatment, wherein the system has at least one blood treatment device, in particular a dialyzer, and at least one tank from which treatment fluid, in particular dialysis fluid, is removed during the carrying out of the blood treatment and/or into which consumed treatment fluid, in particular consumed dialysis fluid, is filled during the carrying out of the blood treatment, wherein the tank is an element of at least one mobile apparatus which can be connected to the blood treatment device such that at least one fluid connection can be established between the tank and the blood treatment device.

Priority: DE20101011465 Applic. Date: 2010-03-15; WO2011EP01261 Applic. Date: 2011-03-14

Inventor: POHLMEIER ROBERT [DE]; HERRENBAUER MICHAEL [DE]; GOEMPEL-KLEIN PATRICIA [DE]; KRAUSE ALFRED [DE]; WEHMEYER WOLFGANG [DE]


Application No.: US20130018279A1  Published: 17/Jan/2013

Title: blood sample collection apparatus and kits

Applicant/Assignee: PATHWAY GENOMICS

Application No.: 12/584153   Filing Date: 01/Sep/2009

Abstract:

Blood sample collection apparatus and kits are devised as easy-to-use, reduced pain devices operable by persons not having medical training or other expertise or knowledge. A flexible strip having adhesives on two portions of a first side accommodate therebetween and absorbent pad and substrate with microstructures. The substrate includes microstructures arranged to gently penetrate or pierce skin and cause a small amount of blood to pass to the external surface of a user's flesh. An absorbent pad receives and absorbs a blood sample therein. The absorbent pad may additionally support a plurality of chemical agents which further advances mobility of blood in the collection system. These chemical agents may include anticoagulants and blood anticlotting agents to facilitate blood transfer from a donor to the absorbent pad. Additionally, these systems may also include a blood preservative to stabilize blood collected for an extended shipping and transfer period. These blood sample collection systems may further include a numbing agent to improve comfort of use.

Priority:

Inventor: PLANTE JAMES [US]; NOVA MICHAEL [US]; BECKER DAVID [US]; NOAEK LUKE [US]


Application No.: US20130022587A1  Published: 24/Jan/2013

Title: Cycloalkyl-Substituted Imidazole Derivative

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 13/550366   Filing Date: 16/Jul/2012

Abstract:

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc

R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group

R4 represents a hydrogen atom or a prodrug group

and Y represents -CH2-CHR5-CH2-NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Priority: JP20100062155 Applic. Date: 2010-03-18; WO2011JP55953 Applic. Date: 2011-03-14

Inventor: NAGATA TSUTOMU [JP]; INOUE MASAHIRO [JP]; ASHIDA YUKA [JP]; NOGUCHI KENGO [JP]; ONO MAKOTO [JP]


Application No.: US20130023001A1  Published: 24/Jan/2013

Title: USE OF A SUBSTRATE IN A METHOD FOR MEASURING THE ACTIVITY OF PROTEOLYTIC ENZYMES

Applicant/Assignee:

Application No.: 13/553920   Filing Date: 20/Jul/2012

Abstract:

The disclosure relates to the use of a proteolytic enzyme substrate of general formula: Q1-Xaa2-Xaa1-rhodamine110-Q2, in which Xaa1 and Xaa2 are amino acids and Q2 is Xaa1-Xaa2-Q1, or an amino acid Xaa3, or a group comprising an aryl group, or H, so as to be able to inhibit, in a blood sample containing a glycosaminoglycan, the anticoagulant capacity of said glycosaminoglycan. The invention also relates to a method for measuring an enzymatic activity using such a substrate and a kit for implementation thereof.

Priority: FR20110056715 Applic. Date: 2011-07-22

Inventor: QUENTIN GERARD [FR]; CARLO AUDREY [FR]; BOULANGER LOISE [FR]


Application No.: US20130023002A1  Published: 24/Jan/2013

Title: USE OF A SUBSTRATE IN A METHOD FOR MEASURING THE ACTIVITY OF AVAILABLE PROTEOLYTIC ENZYMES

Applicant/Assignee:

Application No.: 13/553932   Filing Date: 20/Jul/2012

Abstract:

The disclosure relates to the use of a proteolytic enzyme substrate of general formula: Q1-Xaa2-Xaa1-rhodamine110-Q2, in which: Xaa1 and Xaa2 are amino acids and Q2 is a group comprising an alkyl group

so as to be able to allow, in a blood sample containing a glycosaminoglycan, said glycosaminoglycan to inhibit the coagulation of said blood sample, via which the anticoagulant capacity of the glycosaminoglycan is not disrupted.

Priority: FR20110056714 Applic. Date: 2011-07-22

Inventor: QUENTIN GERARD [FR]; CARLO AUDREY [FR]; BOULANGER LOISE [FR]


Application No.: US20130023721A1  Published: 24/Jan/2013

Title: Extracellular matrix encasement structures and methods

Applicant/Assignee:

Application No.: 13/573566   Filing Date: 24/Sep/2012

Abstract:

A remodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch having an internal region configured to receive a device therein, the bioremodelable material comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least a bioactive component selected from the group consisting of a statin and a chitin derivative

Priority: US201113033102 Applic. Date: 2011-02-23; US2009-394914 Applic. Date: 2009-02-27; US2007-747004 Applic. Date: 2007-05-10

Inventor: MATHENY ROBERT G [US]


Application No.: US20130023813A1  Published: 24/Jan/2013

Title: Drug Delivery Device and Method

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS, INC

Application No.: 13/186259   Filing Date: 19/Jul/2011

Abstract:

Many people need vascular access for procedures such as hemodialysis. It is desirable that this access remain open or patent for the entire duration of the course of treatments. A drug delivery device and methods of using the device are introduced that delivery drug to venous anastomosis of a synthetic vascular access shunt. In some embodiments this device serves as the shunt connecting the target artery and vein to create the vascular access shunt.

Priority:

Inventor: ROORDA WOUTER E [US]


Application No.: US20130028880A1  Published: 31/Jan/2013

Title: APYRASE THERAPY FOR BLEEDING CONDITIONS

Applicant/Assignee: APT THERAPEUTICS, INC

Application No.: 13/522310   Filing Date: 13/Jan/2011

Abstract:

This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are patho-physiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.

Priority: US2010-294725P Applic. Date: 2010-01-13; WO2011US21170 Applic. Date: 2011-01-13

Inventor: CHEN RIDONG [US]; JEONG SOON SEOG [US]


Application No.: US20130028902A1  Published: 31/Jan/2013

Title: OSTEOCALCIN AS A TREATMENT FOR MALE REPRODUCTIVE DISORDERS

Applicant/Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Application No.: 13/574196   Filing Date: 19/Jan/2011

Abstract:

Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-IB signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes.

Priority: US2010-296415P Applic. Date: 2010-01-19; US2010-296339P Applic. Date: 2010-01-19; WO2011US21634 Applic. Date: 2011-01-19

Inventor: KARSENTY GERARD [US]; DUCY PATRICIA F [US]


Application No.: US20130028930A1  Published: 31/Jan/2013

Title: Albumin Derivatives and Variants

Applicant/Assignee: NOVOZYMES BIOPHARMA DK A/S

Application No.: 13/640235   Filing Date: 08/Apr/2011

Abstract:

The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.

Priority: EP20100159450 Applic. Date: 2010-04-09; EP20100174164 Applic. Date: 2010-08-26; EP20110158921 Applic. Date: 2011-03-18; WO2011EP55577 Applic. Date: 2011-04-08

Inventor: PLUMRIDGE ANDREW [GB]; SLEEP DARRELL [GB]; SANDLIE INGER [NO]; ANDERSEN JAN TERJE [NO]; CAMERON JASON [GB]; EVANS LESLIE [GB]; ATHWAL STEVEN [GB]; ALLAN ELIZABETH [GB]; FRIIS ESBEN PETER [DK]


Application No.: US20130030263A1  Published: 31/Jan/2013

Title: Device for Taking a Sample of a Body Fluid and Method for Implementing Same

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON

Application No.: 13/508185   Filing Date: 29/Oct/2010

Abstract:

The invention relates to a device (200) for taking a sample of a body fluid, such as blood, to be incorporated into a fluid circuit of a perfusion (100) of a patient who has a perfusion catheter (104), said device having a tubular structure (202) for connecting to the fluid circuit of the perfusion, provided with a zone for intubation, during use, of a sampling channel (300) comprising a distal end (301)

and a means (203) for holding, during use, in the tubular structure, the part of the sampling channel (300) comprising a distal end (301) in such a way that the distal end (301) is oriented towards the perfusion catheter (104), in the direction of flow (F1) of the perfusion product (102), from a perfusion product reservoir (101) towards the perfusion catheter (104).

Priority: FR20090005330 Applic. Date: 2009-11-05; WO2010FR00712 Applic. Date: 2010-10-29

Inventor: PAZART LIONEL [FR]; WACOGNE BRUNO FRANCOIS MARCEL [FR]; PIERALLI CHRISTIAN GERARD DANIEL [FR]; BOIREAU WILFRID HERVE [FR]; MOREL PASCAL CHARLES SERGE [FR]


Application No.: US20130035288A1  Published: 07/Feb/2013

Title: Resorption Enhancers As Additives To Improve The Oral Formulation Of Non-Anticoagulant Sulfated Polysaccharides

Applicant/Assignee:

Application No.: 13/552569   Filing Date: 18/Jul/2012

Abstract:

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

Priority: US201161509514P Applic. Date: 2011-07-19

Inventor: TURECEK PETER [AT]; VEJDA SUSANNE [AT]


Application No.: US20130035564A1  Published: 07/Feb/2013

Title: REAL TIME INTRAVASCULAR MONITORING DEVICE

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 13/195287   Filing Date: 01/Aug/2011

Abstract:

A real time tissue sampling and analysis system includes a catheter including an elongated body defining at least one internal lumen, a sampling device positionable within the at least one internal lumen of the catheter for collecting a tissue sample, and a biochip disposed within the at least one internal lumen. The biochip includes a substrate for receiving the tissue sample, a marker for interacting with the tissue sample, and a sensor for identifying a characteristic of the tissue sample and transmitting data about the tissue sample to a processing unit for analysis.

Priority:

Inventor: DESHPANDE MANISH [US]; KAPUR TERRI A [US]


Application No.: US20130035951A1  Published: 07/Feb/2013

Title: METHODS AND DEVICES FOR REDUCING TRANSFUSIONS DURING OR AFTER SURGERY AND FOR IMPROVING QUALITY OF LIFE AND FUNCTION IN CHRONIC DISEASE

Applicant/Assignee:

Application No.: 13/576874   Filing Date: 02/Feb/2011

Abstract:

The present invention relates to methods of treating subjects preparing to undergo surgery or methods of treating chronic disease and methods for reducing transfusions and a computer readable storage medium and a physical computing device for carrying out these methods which include: a) receiving a profile of said subject, in a physical computing device, including a level of hemoglobin of said subject, level of creatinine of said subject, and information regarding current or past history of disease

b) applying said level of hemoglobin and said level of creatinine, in said physical computing device, to determine level of transfusion risk

c) applying said information regarding current or past history of disease of said subject, in said physical computing device, to determine level of comorbidity

d) applying said level of hemoglobin, said level of transfusion risk, and said level of comorbidity, in said physical computing device, to determine a patient care plan.

Priority: US2010-300684P Applic. Date: 2010-02-02; WO2011US23498 Applic. Date: 2011-02-02

Inventor: FREY KATHRINE P [US]


Application No.: US20130041241A1  Published: 14/Feb/2013

Title: PECVD COATING METHODS FOR CAPPED SYRINGES, CARTRIDGES AND OTHER ARTICLES

Applicant/Assignee:

Application No.: 13/651299   Filing Date: 12/Oct/2012

Abstract:

A method is disclosed in which a vapor-deposited coating or layer is directly or indirectly applied to at least a portion of the internal wall of the barrel of a capped pre-assembly comprising a barrel, optionally a dispensing portion, and a cap. The cap is secured to the barrel and at least substantially isolates the distal opening of the dispensing portion from pressure conditions outside the cap. A vapor-deposited coating or layer is applied directly or indirectly to at least a portion of the internal wall of the barrel while the pre-assembly is capped. The coating or layer is applied under conditions effective to maintain communication from the barrel lumen to the exterior via the front opening, optionally further via the dispensing portion lumen if present, at the end of the applying step. The capped pre-assembly can be pressure tested easily and rapidly, for example with a test duration between 1 and 60 seconds, to determine whether it has container closure integrity.

Priority: US201113169811 Applic. Date: 2011-06-27; US2010-779007 Applic. Date: 2010-05-12; US2009-222727P Applic. Date: 2009-07-02; US2009-213904P Applic. Date: 2009-07-24; US2009-234505P Applic. Date: 2009-08-17; US2009-261321P Applic. Date: 2009-11-14; US2009-263289P Applic. Date: 2009-11-20; US2009-285813P Applic. Date: 2009-12-11; US2010-298159P Applic. Date: 2010-01-25; US2010-299888P Applic. Date: 2010-01-29; US2010-318197P Applic. Date: 2010-03-26; US2010-333625P Applic. Date: 2010-05-11; US201261636377P Applic. Date: 2012-04-20

Inventor: FELTS JOHN T [US]; FISK THOMAS E [US]; KINNEY SHAWN [US]; WEIKART CHRISTOPHER [US]; HUNT BENJAMIN [US]; RAICHE ADRIAN [US]; FITZPATRICK BRIAN [US]; SAGONA PETER J [US]; STEVENSON ADAM [US]


Application No.: US20130045192A1  Published: 21/Feb/2013

Title: REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS

Applicant/Assignee: ALEXION PHARMACEUTICALS, INC

Application No.: 13/508909   Filing Date: 09/Nov/2010

Abstract:

The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.

Priority: US2009-280897P Applic. Date: 2009-11-09; WO2010US55997 Applic. Date: 2010-11-09

Inventor: MOVALIA MAYUR [US]; ILLINGWORTH ANDREA [US]; FAAS MCKNIGHT SUSAN [US]; ROTHER RUSSELL P [US]


Application No.: US20130046225A1  Published: 21/Feb/2013

Title: IMMUNOACTIVATION BLOOD PERFUSION FILTER FOR THE TREATMENT OF MALIGNANT TUMORS

Applicant/Assignee: NOSE AKO

Application No.: 13/394765   Filing Date: 07/Oct/2010

Abstract:

The invention provides a way of producing a natural immunologically active state in a person by subjecting him to an apheresis procedure with bioincompatible biomaterials for about one hour. To safely control the immunological shock induced by this procedure, the person is put under general anesthesia for about six hours, including the apheresis time and at least an additional five hours thereafter. This immunological activation is useful for treating malignant tumors and diseases related to immunosuppression, such as AIDS. The invention also provides for the use of an apheresis column containing a blood perfusion filter with bioincompatible materials for treating malignant tumors and infectious diseases.

Priority: US2009-249867P Applic. Date: 2009-10-08; WO2010US51832 Applic. Date: 2010-10-07

Inventor: NOSE YUKIHIKO [US]; OHTA KAZUHIDE [JP]; MIYAMOTO HIROSHI [JP]; TAKABA JUNJI [JP]


Application No.: US20130052258A1  Published: 28/Feb/2013

Title: POLYPEPTIDES AND USES THEREOF

Applicant/Assignee: XMEDIC AB

Application No.: 13/497622   Filing Date: 22/Sep/2010

Abstract:

The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 7, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.

Priority: GB20090016576 Applic. Date: 2009-09-22; WO2010GB01778 Applic. Date: 2010-09-22

Inventor: KALLE MARTINA [SE]; KASETTY GOPINATH [SE]; MALMSTEN NILS MARTIN [SE]; PAPAREDDY PRAVEEN [SE]; SCHMIDTCHEN ARTUR [SE]; WALSE BJORN ULRIK [SE]


Application No.: US20130053446A1  Published: 28/Feb/2013

Title: PHARMACEUTICAL PREPARATIONS HAVING INDIVIDUALIZED DOSAGE AND STRUCTURE

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 13/508485   Filing Date: 06/Nov/2010

Abstract:

A manufacturing device capable of creating individualized dosages of pharmaceutical preparations in which a metering system and a means of performing non-destructive chemical analysis of individual manufactured units are controlled by a microprocessor to precisely control the content and structure of each individual unit.

Priority: WO2010US55752 Applic. Date: 2010-11-06; US2009-258670P Applic. Date: 2009-11-06

Inventor: MUZZIO FERNANDO J [US]; TAKHISTOV PAVLO [US]; MICHNIAK-KOHN BOZENA B [US]


Application No.: US20130053546A1  Published: 28/Feb/2013

Title: Use of Anticoagulants in the Production of Recombinant Proteins in the Milk of Transgenic Animals

Applicant/Assignee: PHARMING INTELLECTUAL PROPERTY BV

Application No.: 13/582044   Filing Date: 11/Mar/2011

Abstract:

The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called clots and flakes in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.

Priority: US2010-387665P Applic. Date: 2010-09-29; WO2011NL50166 Applic. Date: 2011-03-11; US2010-314673P Applic. Date: 2010-03-17; EP20100156751 Applic. Date: 2010-03-17

Inventor: NELSON KATHRYN MARGARET [US]; MOSESSON MICHAEL WILLIAM [US]; PUSATERI ANTHONY [US]; FORSBERG ERIK JORDAHL [US]


Application No.: US20130053949A1  Published: 28/Feb/2013

Title: QUICK-CONNECT PROSTHETIC HEART VALVE AND METHODS

Applicant/Assignee: EDWARDS LIFESCIENCES CORPORATION

Application No.: 13/660780   Filing Date: 25/Oct/2012

Abstract:

A heart valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The prosthetic valve has a base stent that is deployed at a treatment site, and a valve component configured to quickly connect to the base stent. The base stent may take the form of a self- or balloon-expandable stent that expands outward against the native valve with or without leaflet excision. The valve component has a non-expandable prosthetic valve and a self- or balloon-expandable coupling stent for attachment to the base stent, thereby fixing the position of the valve component relative to the base stent. The prosthetic valve may be a commercially available valve with a sewing ring and the coupling stent attaches to the sewing ring. The system is particularly suited for rapid deployment of heart valves in a conventional open-heart surgical environment.

Priority: US2009-635471 Applic. Date: 2009-12-10; US2008-139398P Applic. Date: 2008-12-19

Inventor: PINTOR RAFAEL [US]; CHAU MARK [US]; OBA TRAVIS ZENYO [US]; YAMBAO AUGUST R [US]; CAMPBELL LOUIS A [US]; HUNTLEY TAMMY [US]; ZENG QUINGGANG [US]; CRISTEA CAREY L [US]; KALAM FAISAL [US]


Application No.: US20130058904A1  Published: 07/Mar/2013

Title: Method and system for treatment of biological tissue

Applicant/Assignee: FRANCIS LAW GROUP

Application No.: 13/573569   Filing Date: 24/Sep/2012

Abstract:

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.

Priority: US2006-334631 Applic. Date: 2006-01-18

Inventor: MATHENY ROBERT G [US]


Application No.: US20130058906A1  Published: 07/Mar/2013

Title: PROCESS, TUBE AND DEVICE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION

Applicant/Assignee:

Application No.: 13/634020   Filing Date: 11/Mar/2011

Abstract:

The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

Priority: GB20100004072 Applic. Date: 2010-03-11; WO2011IB00684 Applic. Date: 2011-03-11

Inventor: TURZI ANTOINE [CH]


Application No.: US20130058929A1  Published: 07/Mar/2013

Title: FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION OF THROMBI

Applicant/Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Application No.: 13/528125   Filing Date: 20/Jun/2012

Abstract:

Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents.

Priority: US2008-089250 Applic. Date: 2008-10-21; WO2006US38989 Applic. Date: 2006-10-05; US2005-723899P Applic. Date: 2005-10-05

Inventor: MUZYKANTOV VLADIMIR R [US]; GOTTSTEIN CLAUDIA [US]; DING BI-SEN [US]; CINES DOUGLAS B [US]


Application No.: US20130060279A1  Published: 07/Mar/2013

Title: CATHETER WITH SEALED HYDRATABLE HEMOSTATIC OCCLUSION ELEMENT

Applicant/Assignee: CARDIVA MEDICAL, INC

Application No.: 13/224539   Filing Date: 02/Sep/2011

Abstract:

Apparatus for sealing a vascular wall penetration disposed at the end of the tissue tract comprises a shaft, an optional occlusion element, a hydratable hemostatic implant, and a protective sleeve. The apparatus is deployed through the tissue tract with the occlusion element optionally occluding the vascular wall penetration and inhibiting backbleeding therethrough. The hydratable hemostatic implant, which will typically be a biodegradable polymer such as collagen carrying an anti-proliferative agent or coagulation promoter, will then be deployed from the sealing apparatus by retracting the protective sleeve and left in place to enhance closure of the vascular wall penetration with minimum scarring. The hydratable implant will be protected from premature hydration and swelling by a soluble plug covering the implant's distal end prior to sleeve retraction.

Priority:

Inventor: YASSINZADEH ZIA [US]


Application No.: US20130071350A1  Published: 21/Mar/2013

Title: METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS

Applicant/Assignee: BIOPHERESIS TECHNOLOGIES, INC

Application No.: 13/570876   Filing Date: 09/Aug/2012

Abstract:

The present invention refers to a system for inducing an immune response against transformed, infected, or diseased tissue comprising a device for removing only components present in blood or plasma having a molecular weight of 120,000 daltons or less, having an inlet and outlet for connection to a pump and tubing to recirculate the blood or plasma of a patient through the device. Further, the present invention refers to methods of inducing an immune response against transformed, infected, or diseased tissue comprising administering to a patient blood, plasma, or a blood fraction from which only components having a molecular weight of 120,000 daltons or less have been removed, whereby administration of said blood, plasma, or blood fraction induces an immune response against transformed, infected, or diseased tissue in the patient until the transformed, infected, or diseased tissue is reduced in amount.

Priority: US2010-685307 Applic. Date: 2010-01-11; US2000-699003 Applic. Date: 2000-10-26; US1999-316226 Applic. Date: 1999-05-21; US1998-083307 Applic. Date: 1998-05-22

Inventor: LENTZ M RIGDON [DE]


Application No.: US20130071357A1  Published: 21/Mar/2013

Title: IDENTIFICATION, PROLIFERATION IN SITU, HARVESTING, SEPARATION, AND TRANSPLANTATION OF ADULT-DERIVED REGENERATIVE PLURIPOTENT TRANSITIONAL BLASTOMERE-LIKE STEM CELLS AND METHODS OF TREATMENT THEREOF

Applicant/Assignee: HEYGEN, LLC

Application No.: 13/365880   Filing Date: 03/Feb/2012

Abstract:

Non-embryonic transitional blastomere-like stem cells are disclosed. Most preferably, such cells are obtained from the blood after induction by a plant-based compound to proliferate and reverse diapadese into the vasculature or from various tissues of postnatal mammals or humans (using tissue biopsied from the mammal or human), are in the range of 3-5 microns, have a normal karyotype, and do not spontaneously differentiate in situ (in vivo) or in serum-free medium without differentiation inhibitors. These non-embryonic transitional blastomere-like stem cells typically express CD66e, CEA-CAM-1, CD10, SSEA (SSEA-1, SSEA-3, and SSEA-4), telomerase, Sonic hedgehog, but do not typically express Nanog, Nanos, BCl-2 or CXCR-4. Such transitional blastomere-like pluripotent stem cells can be differentiated into epiblast-like stem cells, ectodermal, mesodermal, and endodermal tissues, but NOT placental tissues or germ cells. Moreover, when implanted into a mammal or human, such cells will not be teratogenic.

Priority: US201213363370 Applic. Date: 2012-01-31; US201161437705P Applic. Date: 2011-01-31

Inventor: YOUNG HENRY E [US]


Application No.: US20130084310A1  Published: 04/Apr/2013

Title: COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTS

Applicant/Assignee: DEPUY MITEK, INC

Application No.: 13/250086   Filing Date: 30/Sep/2011

Abstract:

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.

Priority:

Inventor: SENGUN MEHMET Z [US]; PARRISH WILLIAM [US]; WHITTAKER GREGORY R [US]; FIFOLT DOUGLAS A [US]; STORY BROOKS J [US]


Application No.: US20130095095A1  Published: 18/Apr/2013

Title: METHOD FOR TREATING THROMBOTIC DISORDERS USING QUERCETIN-CONTAINING COMPOSITIONS

Applicant/Assignee:

Application No.: 13/272508   Filing Date: 13/Oct/2011

Abstract:

A method for treating thrombotic disorders using a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid. Also disclosed is a method of improving the efficacy of a blood thinning medication by co-administering a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid to a subject being treated with a blood thinning medication.

Priority:

Inventor: LINES THOMAS CHRISTIAN [US]


Application No.: US20130102948A1  Published: 25/Apr/2013

Title: PORTABLE BLOOD FILTRATION DEVICES, SYSTEMS, AND METHODS

Applicant/Assignee:

Application No.: 13/641559   Filing Date: 24/Mar/2011

Abstract:

A blood filtration device, system, and method that can and selectively remove or reduce an unwanted, in certain cases unknown, substance from a patient's blood stream. More specifically, a specific size or size range of unwanted substance is selectively removed. The unwanted substance includes one or more of a pathogen, a toxin, an activated cell, and an administered drug. The device and system employ a microfluidic separation device that minimizes thrombogenesis and can permit the use of anticoagulants to be avoided. The device or system can be portable and can include its own power supply. Sensors in the system may monitor for the presence and/or concentration of unwanted species including pathogens or drugs and invoke a blood cleansing process responsively to the sensor signals in closed loop control process. The control may combine the infusion of therapeutic agents into the blood of a patient as well.

Priority: US2010-325765P Applic. Date: 2010-04-19; WO2011US29854 Applic. Date: 2011-03-24

Inventor: REICH ILAN K [US]; LEONARD EDWARD F [US]; MERMELSTEIN FRED [US]


Application No.: US20130116597A1  Published: 09/May/2013

Title: METHOD AND APPARATUS FOR ACQUIRING BLOOD FOR TESTING

Applicant/Assignee: PHENOMENEX, INC

Application No.: 13/668062   Filing Date: 02/Nov/2012

Abstract:

A blood sampling device is provided having holder with a manipulating end and an absorbent probe on the opposing end. The probe is of hydrophilic polymer sized to directly absorb a predetermined volume of up to about 30 microliters of blood. Ribs on the holder position the probe within a compartment of a container to prevent contact with the container. The ribs also position the probe within extraction wells.

Priority: US201161555956P Applic. Date: 2011-11-04

Inventor: RUDGE JAMES [US]; RAHN PETER [US]; WELSH EMMET [US]; GUO YIBO [US]; SANCHEZ CARL [US]


Application No.: US20130130382A1  Published: 23/May/2013

Title: AUTOSERUM-CONTAINING BONE MARROW CELL CULTURE SYSTEM, AUTOSERUM-CONTAINING BONE MARROW CELL CULTURE METHOD, AND METHOD FOR PRODUCING MEDICINAL COMPOSITION COMPRISING AUTOSERUM-CONTAINING CULTURED BONE MARROW CELLS AS ACTIVE INGREDIENT

Applicant/Assignee: SAPPORO MEDICAL UNIVERSITY

Application No.: 13/813766   Filing Date: 03/Aug/2011

Abstract:

To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state

an autoserum-containing bone marrow cell culture method

and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.

Priority: JP20100174902 Applic. Date: 2010-08-03; JP20100174903 Applic. Date: 2010-08-03; JP20100218275 Applic. Date: 2010-09-29; WO2011JP67758 Applic. Date: 2011-08-03

Inventor: HONMOU OSAMU [JP]; YOSHIKAWA YOSHIHIRO [JP]; MORIKAWA NAOMI [JP]


Application No.: US20130137586A1  Published: 30/May/2013

Title: STABILIZATION OF NUCLEIC ACIDS IN CELL MATERIAL-CONTAINING BIOLOGICAL SAMPLES

Applicant/Assignee: QIAGEN GMBH

Application No.: 13/701439   Filing Date: 01/Jun/2011

Abstract:

The present invention relates to the use of an aqueous system for stabilizing cell material-containing biological samples while preserving the cell morphology of the cell material and to a method for stabilizing nucleic acids in cell material-containing biological samples while preserving the cell morphology of the cell material.

Priority: EP20100005711 Applic. Date: 2010-06-02; WO2011EP59162 Applic. Date: 2011-06-01

Inventor: ERBACHER CHRISTOPH [DE]; KIRCHMANN MARKUS [DE]; BAUMHOF PATRICK [DE]; SCHICK PETRINA [DE]


Application No.: US20130137702A1  Published: 30/May/2013

Title: ANTICOAGULANT REVERSAL AGENTS

Applicant/Assignee: PEROSPHERE INC

Application No.: 13/688442   Filing Date: 29/Nov/2012

Abstract:

Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds.

Priority: US201161564559P Applic. Date: 2011-11-29; US201261614292P Applic. Date: 2012-03-22; US201261641698P Applic. Date: 2012-05-02; US201261666291P Applic. Date: 2012-06-29

Inventor: STEINER SOLOMON S [US]; LAULICHT BRYAN E [US]; BAKHRU SASHA H [US]; MATHIOWITZ EDITH [US]


Application No.: US20130143226A1  Published: 06/Jun/2013

Title: BIOLOGICAL FLUID SAMPLING AND STORAGE APPARATUS FOR REMOTE USE

Applicant/Assignee: SPOT ON SCIENCES, INC

Application No.: 13/817442   Filing Date: 25/Jul/2011

Abstract:

An apparatus for sampling and storing biological fluids from a human or animal subject is provided. In one embodiment of the present disclosure, the apparatus includes a main body, lancet carrier or hub, lancet, lancet trigger, capillary tube, and sample compartments for collecting and storing dried blood and other bodily fluids. The lancet hub supports a lancet and provides for moving the lancet longitudinally between a first retracted position and a second extended position. The device includes a capillary tube having an internal diameter sized to draw and retain fluid from a contacted source using capillary action. The main body of the apparatus further includes a sample compartment for holding sampling and storage materials. In at least one embodiment of the present disclosure, the sample compartment can be accessed by lifting sample compartment lid. Also included is a new "fan" or "daisy" shaped collection material format for use in collecting and preserving samples.

Priority: US2010-377323P Applic. Date: 2010-08-26; WO2011US45167 Applic. Date: 2011-07-25

Inventor: HILL JEANETTE [US]; HILL JAMES [US]


Application No.: US20130143322A1  Published: 06/Jun/2013

Title: METHOD FOR CONTROLLING PROLIFERATION OF CORD BLOOD HEMATOPOIETIC STEM CELLS AND USE THEREOF

Applicant/Assignee: JMS CO., LTD

Application No.: 13/754336   Filing Date: 30/Jan/2013

Abstract:

The present invention provides a method for controlling the proliferation and differentiation of cord blood-derived hematopoietic stem cells with excellent safety when proliferating them by culturing. The hematopoietic stem cells are inoculated into a medium containing a sonicated liquid component of cord blood. The proliferation and differentiation of the cord blood hematopoietic stem cells can be inhibited in the presence of the sonicated liquid component of cord blood. On the contrary, the proliferation of cord blood hematopoietic stem cells can be accelerated by inoculating the hematopoietic stem cells into a medium containing a non-sonicated liquid component of cord blood. Thus, according to the present invention, by using serum derived from cord blood, it is possible to regulate the inhibition of the proliferation and differentiation of cord blood hematopoietic stem cells and the acceleration of the proliferation of the same as desired.

Priority: JP20090015639 Applic. Date: 2009-01-27; JP20100006277 Applic. Date: 2010-01-14; US201113146613 Applic. Date: 2011-07-27; WO2010JP50795 Applic. Date: 2010-01-22

Inventor: HIRAI SATOSHI [JP]; OGATA KASUMI [JP]


Application No.: US20130144266A1  Published: 06/Jun/2013

Title: METHODS FOR REDUCING THE BLOOD PRIMING VOLUME AND MEMBRANE SURFACE AREA IN MICROFLUIDIC LUNG ASSIST DEVICES

Applicant/Assignee: THE CHARLES STARK DRAPER LABORATORY, INC

Application No.: 13/705795   Filing Date: 05/Dec/2012

Abstract:

A device and method for oxygenating blood is disclosed herein. The device includes a plurality of passive mixing elements that causes a fluid to mix as it flows through the device. The passive mixing elements continually expose new red blood cells to the portion of the flow channel where oxygenation can occur. Accordingly, in some implementations, the device and method uses less blood to prime the device and allows for the oxygenation of blood with a substantial shorter flow channel when compared to conventional oxygenation methods and devices.

Priority: US201161567104P Applic. Date: 2011-12-05

Inventor: BORENSTEIN JEFFREY T [US]; CHAREST JOSEPH L [US]; HSIAO JAMES C [US]; KNIAZEVA TATIANA [US]; KIM ERNEST S [US]; EPSHTEYN ALLA [US]; KOLACHALAMA VIJAYA [US]


Application No.: US20130149691A1  Published: 13/Jun/2013

Title: Methods, Reagents and Kits for Preservation of Nucleic Acids in Biological Samples

Applicant/Assignee: NORGEN BIOTEK CORP

Application No.: 13/524560   Filing Date: 15/Jun/2012

Abstract:

Provided is a nucleic acid preservative comprising at least one reducing agent, at least one chaotropic substance, at least one polyamine substance and at least one chelating agent and uses thereof, and a method for the preservation of nucleic acids in a biological sample. Further provided are kits for use in the preservation of nucleic acids in a biological sample, and more particularly, a blood sample.

Priority: US201161498042P Applic. Date: 2011-06-17; US201161543532P Applic. Date: 2011-10-05; US201161566060P Applic. Date: 2011-12-02

Inventor: HAJ-AHMAD YOUSEF [CA]


Application No.: US20130156698A1  Published: 20/Jun/2013

Title: TISSUE TARGETING

Applicant/Assignee: MOMENTA PHARMACEUTICALS, INC

Application No.: 13/641278   Filing Date: 15/Apr/2011

Abstract:

Methods and compositions related to targeting agents to tumor tissue are described.

Priority: US2010-325146P Applic. Date: 2010-04-16; WO2011US32771 Applic. Date: 2011-04-15

Inventor: ZHOU HE [CN]; COCHRAN EDWARD [US]; KISHIMOTO TAKASHI KEI [US]


Application No.: US20130158430A1  Published: 20/Jun/2013

Title: AUTONOMOUS, AMBULATORY ANALYTE MONITOR OR DRUG DELIVERY DEVICE

Applicant/Assignee: INTUITY MEDICAL, INC

Application No.: 13/669366   Filing Date: 05/Nov/2012

Abstract:

The invention relates to analyte monitoring/drug delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The invention can optionally provide for calibration without intervention of the user and can also provide for semi-continuous monitoring for day and night time. The invention can provide up to four, or more, weeks of operation. The invention can provide for a device that is relatively small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents.

Priority: US2005-311667 Applic. Date: 2005-12-20; US2002-131268 Applic. Date: 2002-04-23; US2002-355195P Applic. Date: 2002-02-08

Inventor: ACETI JOHN GREGORY [US]; MCBRIDE STERLING EDUARD [US]; MORONEY RICHARD MORGAN [US]; GREGORY CHRISTOPHER CARTER [US]; ZANZUCCHI PETER JOHN [US]


Application No.: US20130160532A1  Published: 27/Jun/2013

Title: FLUID INJECTION AND SAFETY SYSTEM

Applicant/Assignee: OPTISCAN BIOMEDICAL CORPORATION

Application No.: 13/619432   Filing Date: 14/Sep/2012

Abstract:

Various medical systems and methods are described, including a medical monitoring system. The medical monitoring system can have a fluid system configured to receive bodily fluid and optically analyze said fluid to determine analyte concentration. The fluid system can have a removable portion. The removable portion can have an opening with a port. The system can also have a container configured to contain anticoagulant. The container can have a portion configured to mate with the port of the removable portion. The container can be further configured to not fit into a conventional luer fitting. An anti-coagulant insertion apparatus is also described. The apparatus can have a syringe, a dock with a port, and an adapter configured to connect the syringe to the port. The dock can also have a tab configured to move with the port.

Priority: US2008-123422 Applic. Date: 2008-05-19; US2007-939023P Applic. Date: 2007-05-18; US2007-979374P Applic. Date: 2007-10-11

Inventor: RIVAS GIL [US]; BUTLER MICHAEL [US]; CHIOU JEFFREY T [US]; LIM EUGENE [US]


Application No.: US20130169962A1  Published: 04/Jul/2013

Title: SYSTEMS FOR MEASURING PROPERTIES OF A PHYSIOLOGICAL FLUID SUSPENSION

Applicant/Assignee: AGGREDYNE, INC

Application No.: 13/547729   Filing Date: 12/Jul/2012

Abstract:

A method of evaluating a property of a physiological fluid suspension comprises measuring a value of the property of a liquid portion of the physiological fluid suspension via light scattering, and comparing the measured value with a reference value to evaluate the property of the liquid portion of the physiological fluid suspension.

Priority: US2009-398480 Applic. Date: 2009-03-05; US2008-068354P Applic. Date: 2008-03-05

Inventor: SUKAVANESHVAR SIVAPRASAD [US]; TEITEL EDWARD R [US]; MOHAMMAD SYED F [US]


Application No.: US20130178425A1  Published: 11/Jul/2013

Title: METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: 13/782421   Filing Date: 01/Mar/2013

Abstract:

Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation.

Priority: WO2011US48909 Applic. Date: 2011-08-24; US2010-380026P Applic. Date: 2010-09-03

Inventor: HIGGINS JOEL [US]; HOEPPNER JACY [US]; WOODELL-MAY JENNIFER [US]


Application No.: US20130178834A1  Published: 11/Jul/2013

Title: Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases

Applicant/Assignee: SOMERSET GROUP ENTERPRISES, INC

Application No.: 13/737930   Filing Date: 09/Jan/2013

Abstract:

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with cold plasma and optionally with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

Priority: US201261584453P Applic. Date: 2012-01-09

Inventor: GREENBERG DAVID G [US]; PURITZ SCOTT [US]; KOUTCHMA TATIANA [US]; WALTERSPIEL JUAN N [US]


Application No.: US20130178923A1  Published: 11/Jul/2013

Title: Heat Exchange Catheters with Bi-Directional Fluid Flow and Their Methods of Manufacture and Use

Applicant/Assignee: ZOLL CIRCULATION, INC

Application No.: 13/631076   Filing Date: 28/Sep/2012

Abstract:

Closed loop heat exchange catheters having bi-directional flow heat exchange regions and their methods of manufacture and use. The heat exchange region may be formed of expandable or non-expandable tubular conduit(s) that are configured in a series of loops or coiled configuration defining a supply flow path and a return flow path through which heat exchange medium is circulated. The individual loops of convolutions of the coiled configuration may be the same or different size. In some embodiments, the tubular conduit(s) may be passed through generally transverse bore holes formed in a catheter shaft so that the loops or convolutions of protrude from the catheter shaft.

Priority: US201161542024P Applic. Date: 2011-09-30

Inventor: DABROWIAK JEREMY THOMAS [US]


Application No.: US20130180339A1  Published: 18/Jul/2013

Title: PRESSURE SENSING METHODS, DEVICES, AND SYSTEMS

Applicant/Assignee: NXSTAGE MEDICAL, INC

Application No.: 13/825310   Filing Date: 23/Sep/2011

Abstract:

A pressure measuring device has tubing with an inline "pillow" portion that is more flexible than the tubing portion. The pillow portion may be created by heating a portion of a length of medical tubing and forcing air into the heated portion to expand, and thin, its walls. The tubing and pillow portion may be used in a negatively pressurized portion of a blood circuit such as an arterial return line. An assembly of interleaved support members adhesively bonded to the pillow portion holds the pillow portion in an expanded state even under negative pressure. Further, when the pillow portion tries to collapse, the interleaved support members compress a strain gauge to provide a pressure signal corresponding to the negative pressure exerted by the fluid therewithin.

Priority: US2010-385732P Applic. Date: 2010-09-23; WO2011US53141 Applic. Date: 2011-09-23

Inventor: BRUGGER JAMES M [US]


Application No.: US20130183363A1  Published: 18/Jul/2013

Title: PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS

Applicant/Assignee:

Application No.: 13/570786   Filing Date: 09/Aug/2012

Abstract:

Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial, substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidin alone or in combination with salicylic acid or one of its salts.

Priority: EP20030002292 Applic. Date: 2003-02-03; US2009-460786 Applic. Date: 2009-07-24; US2004-769961 Applic. Date: 2004-02-02

Inventor: POLASCHEGG HANS-DIETRICH [AT]


Application No.: US20130183638A1  Published: 18/Jul/2013

Title: METHODS, INSERTS, AND SYSTEMS USEFUL FOR ENDODONTIC TREATMENT

Applicant/Assignee:

Application No.: 13/811567   Filing Date: 20/Jul/2011

Abstract:

Described are devices, methods, inserts, and systems useful in endodontic treatments, involving, for example, a shaped regenerative endodontic insert comprising platelet-fibrin matrix.

Priority: WO2011US44644 Applic. Date: 2011-07-20; US2010-367180P Applic. Date: 2010-07-23

Inventor: GEISLER TODD [US]; GEISTER GRAHAM [US]; GEISLER JAMISON [US]


Application No.: US20130189342A1  Published: 25/Jul/2013

Title: HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY

Applicant/Assignee: TITAN PHARMACEUTICALS, INC

Application No.: 13/634535   Filing Date: 16/Mar/2011

Abstract:

The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.

Priority: US2010-314465P Applic. Date: 2010-03-16; WO2011US28727 Applic. Date: 2011-03-16

Inventor: PATEL RAJESH A [US]; BHONSLE SUNIL R [US]


Application No.: US20130190197A1  Published: 25/Jul/2013

Title: METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING COLORECTAL CANCER

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 13/584369   Filing Date: 13/Aug/2012

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2010-757925 Applic. Date: 2010-04-09; US2009-587385 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Application No.: US20130190653A1  Published: 25/Jul/2013

Title: DEVICE FOR BLOOD COLLECTION FROM THE PLACENTA AND THE UMBILICAL CORD

Applicant/Assignee:

Application No.: 13/688739   Filing Date: 29/Nov/2012

Abstract:

A device is provided for blood extraction and collection from the placenta and/or the umbilical cord through a system that combines the collection of the blood falling under gravity, together with a suction system facilitating this fall. Thus, a larger amount of blood can be extracted than is obtained by conventional gravity systems without posing a health risk to the mother, allowing a controlled suction that prevents premature detachment of the placenta.

Priority: ES20120031607 Applic. Date: 2012-10-18; US201213386927 Applic. Date: 2012-01-25

Inventor: ALVAREZ RAMOS ANGEL GABRIEL [ES]


Application No.: US20130190674A1  Published: 25/Jul/2013

Title: USING PHYSIOLOGICAL DATA IN A MEDICAL DEVICE

Applicant/Assignee: FENWAL, INC

Application No.: 13/743922   Filing Date: 17/Jan/2013

Abstract:

Systems and methods for using physiological data in a medical device are disclosed. The physiological data may be measured by a vital sign reader and received by a processing circuit associated with the medical device. The processing circuit may automatically adjust the operation of the medical device during a medical procedure based on the physiological data. In some implementations, the processing circuit may mirror a memory partition to a redundant storage device, allowing for uninterrupted execution of the medical procedure in the event of a memory failure condition.

Priority: US201261589755P Applic. Date: 2012-01-23; US201261637694P Applic. Date: 2012-04-24

Inventor: CASE BRIAN C [US]; PRENDERGAST JONATHAN [US]; FOSTER JOSEPH M [US]; MOSKAL WITOLD [US]


Application No.: US20130190724A1  Published: 25/Jul/2013

Title: PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS

Applicant/Assignee:

Application No.: 13/571107   Filing Date: 09/Aug/2012

Abstract:

Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidin alone or in combination with salicylic acid or one of its salts.

Priority: EP20030002292 Applic. Date: 2003-02-03; US2009-460787 Applic. Date: 2009-07-24; US2004-769961 Applic. Date: 2004-02-02

Inventor: POLASCHEGG HANS-DIETRICH [AT]


Application No.: US20130190854A1  Published: 25/Jul/2013

Title: DRUG-ELUTING STENT AND DELIVERY SYSTEM WITH TAPERED STENT IN SHOULDER REGION

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 13/727327   Filing Date: 26/Dec/2012

Abstract:

A drug-eluting stent delivery system for the treatment of edge restenosis in a blood vessel. The drug-eluting stent delivery system has a balloon disposed about at least a portion of a catheter, the balloon having a first end and a second end and a working length therebetween, the first end and the second end each including a tapered portion, each tapered portion being attached to the catheter, the balloon being inflatable from a collapsed configuration to an inflated configuration. A drug-eluting stent contacts a wall of the blood vessel to maintain the patency of the vessel. The drug-eluting stent has a first end and a second end, the first end and the second end each including a tapered portion, wherein the drug-eluting stent is disposed over the balloon such that at least a portion of the first end and the second end of the balloon are covered by the tapered drug-eluting stent.

A method for making the same is also disclosed herein.

Priority: US201113285627 Applic. Date: 2011-10-31; US2006-646781 Applic. Date: 2006-12-28; US2003-353219 Applic. Date: 2003-01-27

Inventor: PACETTI STEPHEN DIRK [US]


Application No.: US20130192349A1  Published: 01/Aug/2013

Title: METHODS, DEVICES, AND SYSTEMS FOR MEASURING PHYSICAL PROPERTIES OF FLUID

Applicant/Assignee:

Application No.: 13/742244   Filing Date: 15/Jan/2013

Abstract:

Disclosed herein are devices for measuring, at one or more time points, one or more properties or changes in properties of a fluid sample. The devices may comprise a chamber defining an internal volume of the device suitable for receiving and retaining the fluid sample

a plurality of layers, the plurality comprising at least a first layer below the chamber, at least a second layer above the chamber, and a substrate layer between the first and second layers, wherein: the substrate layer is linked to at least one suspended element located within the chamber

the suspended element is linked to the substrate layer by at least two compliant structures located within the chamber

and the suspended element is configured to oscillate upon application of an actuating signal to at least one electrically conductive path, which runs across at least two of the compliant structures and the suspended element. Related methods and uses are also disclosed.

Priority: US201261587020P Applic. Date: 2012-01-16

Inventor: RAMKUMAR ABHISHEK [US]; YOSHIMIZU NORIMASA [US]


Application No.: US20130195959A1  Published: 01/Aug/2013

Title: LYOPHILIZED PLATELET LYSATES

Applicant/Assignee:

Application No.: 13/358797   Filing Date: 26/Jan/2012

Abstract:

The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the platelet source, and lysing the platelets in the platelet rich portion to form a plurality of lysates. An additional step includes lyophilizing the lysates to form lyophilized platelet lysates in a composition with released concentrations of available growth factors, cytokines, and chemokines. In one example, at 30%, by platelet count, of platelets from a platelet source can be lysed using this process.

Priority:

Inventor: PATEL AMIT [US]


Application No.: US20130197475A1  Published: 01/Aug/2013

Title: INJECTOR

Applicant/Assignee: NEW INJECTION SYSTEMS LTD

Application No.: 13/637053   Filing Date: 25/Mar/2011

Abstract:

An injector for delivering medicament comprises a collapsible container (1002) for containing the liquid medicament, a normally-closed valve (1004) coupled to the collapsible container (1002) for retaining the liquid medicament within the collapsible container and an injection means (1006) for delivering the liquid medicament from the collapsible container. The liquid medicament is maintained under pressure by a pressurising means (1003) which pressurises the liquid medicament such that it is delivered by the injection means (1006) when the normally-closed valve (1004) is opened.

Priority: GB20100005014 Applic. Date: 2010-03-25; GB20100006781 Applic. Date: 2010-04-23; GB20100008406 Applic. Date: 2010-05-20; GB20100008640 Applic. Date: 2010-05-25; GB20100009896 Applic. Date: 2010-06-14; GB20100009954 Applic. Date: 2010-06-15; GB20100010403 Applic. Date: 2010-06-22; GB20100013738 Applic. Date: 2010-08-17; WO2011GB00437 Applic. Date: 2011-03-25

Inventor: DUNN STEPHEN TERENCE [GB]


Application No.: US20130197667A1  Published: 01/Aug/2013

Title: Acellular Vascular Products

Applicant/Assignee:

Application No.: 13/876429   Filing Date: 26/Sep/2011

Abstract:

A product comprising a natural acellular xenogenic vascular tissue matrix having at least an 80% reduction in DNA content as compared to an untreated control vascular tissue matrix and being antigenically inert by being substantially free of epitopes capable of reacting with pre-formed human antibodies and also without having the ability to substantially activate complement. The invention also includes methods of preparing such products and uses of the products especially in bypass surgery.

Priority: GB20100016150 Applic. Date: 2010-09-27; GB20100020846 Applic. Date: 2010-12-09; WO2011GB51817 Applic. Date: 2011-09-26

Inventor: INGHAM EILEEN [GB]; FISHER JOHN [GB]; WILSHAW STACY-PAUL [GB]


Application No.: US20130202550A1  Published: 08/Aug/2013

Title: NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/754727   Filing Date: 30/Jan/2013

Abstract:

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

Priority: US201261592554P Applic. Date: 2012-01-30

Inventor: DOCKAL MICHAEL [AT]; SCHEIFLINGER FRITZ [AT]; KNAPPE SABINE [AT]; TILL SUSANNE [AT]; HAI TON [US]; SANDERS PAUL [US]


Application No.: US20130204179A1  Published: 08/Aug/2013

Title: Methods and Systems for Delivering Substances Into Luminal Walls

Applicant/Assignee: ANGIOSCORE, INC

Application No.: 13/707401   Filing Date: 06/Dec/2012

Abstract:

Angioplasty and other dilatation devices are provided with scoring elements which incorporate a drug to be delivered to a body lumen, typically a blood vessel. The non-cutting scoring elements have drugs and other active substances coated over a portion thereof or incorporated within internal structure of the element so that the drug is released into the luminal wall closely associated diseased regions of the body lumen as the non-cutting scoring structure is radially expanded into the wall.

Priority: US2006-411635 Applic. Date: 2006-04-26; US2005-680450P Applic. Date: 2005-05-11

Inventor: KONSTANTINO EITAN [US]; KONSTANTINO MICHAL [US]


Application No.: US20130209444A1  Published: 15/Aug/2013

Title: NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/754575   Filing Date: 30/Jan/2013

Abstract:

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Priority: US201261592549P Applic. Date: 2012-01-30

Inventor: DOCKAL MICHAEL [AT]; SCHEIFLINGER FRITZ [AT]; KNAPPE SABINE [AT]; TILL SUSANNE [AT]; HAI TON [US]; SANDERS PAUL [US]; DANDE PRASAD [US]; JIANG CONG [US]


Application No.: US20130209985A1  Published: 15/Aug/2013

Title: SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS

Applicant/Assignee:

Application No.: 13/757080   Filing Date: 01/Feb/2013

Abstract:

Disclosed are devices for collecting and stabilizing blood or plasma and which contain an anti-coagulant, an antiplatelet agent, and a solubilization agent, and which may optionally include at least one other blood stabilization agent. Methods of making and using the devices in clinical medicine are also provided.

Priority: US201261594152P Applic. Date: 2012-02-02

Inventor: HOKE RANDAL A [US]; DUDARONEK JUSTYNA M [US]; MOSKOWITZ KEITH A [US]; SINQUETT FRANK [US]


Application No.: US20130211449A1  Published: 15/Aug/2013

Title: CLOTTING CASCADE INITIATING APPARATUS AND METHODS OF USE AND METHODS OF CLOSING WOUNDS

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 13/852094   Filing Date: 28/Mar/2013

Abstract:

Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US201213724520 Applic. Date: 2012-12-21; US2006-337278 Applic. Date: 2006-01-23; US2002-291278 Applic. Date: 2002-11-08; US2000-732423 Applic. Date: 2000-12-07; US1998-212080 Applic. Date: 1998-12-15; US1997-069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]


Application No.: US20130220925A1  Published: 29/Aug/2013

Title: METHODS AND SYSTEMS FOR PROVIDING RED BLOOD CELL PRODUCTS WITH REDUCED PLASMA

Applicant/Assignee: FENWAL, INC

Application No.: 13/835127   Filing Date: 15/Mar/2013

Abstract:

Methods and systems for processing and conditioning red blood cells are disclosed. The methods and systems may be used to make a readily transfusible red blood cell product with reduced plasma. In general, the plasma content of the supernatant of the red blood cell product is no greater than about 15%. The red blood cell products are prepared using the disclosed methods and systems remain transfusible for up to 42 days.

Priority: US201213502934 Applic. Date: 2012-04-19; WO2010US50036 Applic. Date: 2010-09-23; US2009-254550P Applic. Date: 2009-10-23

Inventor: MIN KYUNGYOON [US]; RADWANSKI KATHERINE [US]


Application No.: US20130224123A1  Published: 29/Aug/2013

Title: NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER

Applicant/Assignee: ALKERMES PHARMA IRELAND LIMITED

Application No.: 13/693858   Filing Date: 04/Dec/2012

Abstract:

The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US2008-292091 Applic. Date: 2008-11-12; US2003-357514 Applic. Date: 2003-02-04; US2002-353230P Applic. Date: 2002-02-04

Inventor: WERTZ CHRISTIAN F [US]; RYDE NIELS P [US]


Application No.: US20130225595A1  Published: 29/Aug/2013

Title: METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION IN A PATIENT NOT HAVING IDIOPATHIC PULMONARY FIBROSIS

Applicant/Assignee: GILEAD SCIENCES, INC

Application No.: 13/830211   Filing Date: 14/Mar/2013

Abstract:

There is provided a method of treating pulmonary hypertension in a patient in need thereof, said method comprising: administering a therapeutically effective amount of ambrisentan to the patient with pulmonary arterial hypertension, wherein the patient has been determined not to have idiopathic pulmonary fibrosis.

Priority: US201213571039 Applic. Date: 2012-08-09; US201213536001 Applic. Date: 2012-06-28; US201261605002P Applic. Date: 2012-02-29

Inventor: GILLIES HUNTER CAMPBELL [US]; PESCHEL TOBIAS [US]; PIZZUTI DAVID J [US]


Application No.: US20130226032A1  Published: 29/Aug/2013

Title: PORTABLE DEVICE FOR EX VIVO STIMULATION OF WHOLE BLOOD

Applicant/Assignee: HITACHI CHEMICAL RESEARCH CENTER, INC, HITACHI CHEMICAL COMPANY, LTD

Application No.: 13/883269   Filing Date: 31/Oct/2011

Abstract:

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.

Priority: US201161443907P Applic. Date: 2011-02-17; US2010-410223P Applic. Date: 2010-11-04; WO2011US58624 Applic. Date: 2011-10-31

Inventor: MITSUHASHI MASATO [US]; MURAKAMI TAKU [US]


Application No.: US20130226149A1  Published: 29/Aug/2013

Title: APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: 13/663637   Filing Date: 30/Oct/2012

Abstract:

An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Priority: US2006-442631 Applic. Date: 2006-05-26; US2004-932882 Applic. Date: 2004-09-02; US2003-445381 Applic. Date: 2003-05-23; US2002-383013P Applic. Date: 2002-05-24

Inventor: WOODELL-MAY JENNIFER E [US]


Application No.: US20130228516A1  Published: 05/Sep/2013

Title: AMBULATORY ULTRAFILTRATION DEVICE, RELATED METHODS AND A COMPUTER PROGRAM PRODUCT

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 13/808770   Filing Date: 16/Jun/2011

Abstract:

An ambulatory ultrafiltration device includes a blood filter that has a blood side or fluid communication with the vascular system of the subject, an ultrafiltrate side, and a semipermeable membrane disposed between the blood side and the ultrafiltrate side. The ambulatory ultrafiltration also includes a buffer vessel in fluid communication with the blood side of the blood filter, and a blood pump. The blood pump is controlled to alternate between a withdrawal phase and a return phase. In the withdrawal phase, blood is withdrawn on a blood path from the subject via the blood filter to the buffer vessel. In the return phase, blood is returned from the buffer vessel to the subject on the blood path. The blood filter is arranged to remove ultrafiltrate from the blood during at least one of the withdrawal and return phases.

Priority: SE20100050739 Applic. Date: 2010-07-05; US2010-361454P Applic. Date: 2010-07-05; WO2011EP60019 Applic. Date: 2011-06-16

Inventor: JONSSON LENNART [SE]; STERNBY JAN [SE]; WIESLANDER ANDERS [SE]


Application No.: US20130230497A1  Published: 05/Sep/2013

Title: Renovation And Repopulation Of Decellularized Tissues And Cadaveric Organs By Stem Cells

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 13/863308   Filing Date: 15/Apr/2013

Abstract:

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Priority: US2010-823063 Applic. Date: 2010-06-24; US2007-980012 Applic. Date: 2007-10-29; US2002-074976 Applic. Date: 2002-02-13; US2001-268560P Applic. Date: 2001-02-14

Inventor: HARIRI ROBERT J [US]


Application No.: US20130230501A9  Published: 05/Sep/2013

Title: Cycloalkyl-Substituted Imidazole Derivative

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 13/550366   Filing Date: 16/Jul/2012

Abstract:

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc

R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group

R4 represents a hydrogen atom or a prodrug group

and Y represents -CH2-CHR5-CH2-NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Priority: JP20100062155 Applic. Date: 2010-03-18; WO2011JP55953 Applic. Date: 2011-03-14

Inventor: NAGATA TSUTOMU [JP]; INOUE MASAHIRO [JP]; ASHIDA YUKA [JP]; NOGUCHI KENGO [JP]; ONO MAKOTO [JP]


Application No.: US20130233803A1  Published: 12/Sep/2013

Title: METHOD AND APPARATUS FOR PRODUCING PLATELET RICH PLASMA AND/OR PLATELET CONCENTRATE

Applicant/Assignee:

Application No.: 13/869350   Filing Date: 24/Apr/2013

Abstract:

Platelet rich plasma and/or platelet concentrate is prepared by placing whole blood in a first chamber of a sterile processing disposable having two chambers. The processing disposable is subjected to a first centrifugation to separate red blood cells, and the resulting platelet rich plasma supernatant is decanted to the second chamber. The processing disposable is subjected to a second centrifugation to concentrate platelets. A volume of the platelet poor plasma supernatant in the second chamber is removed, and the platelets are re-suspended in the remaining plasma. The second chamber may contain anticoagulant to preclude aggregation of the platelets.

Priority: US2008-149127 Applic. Date: 2008-04-28; US2002-106248 Applic. Date: 2002-03-27; US2000-582730 Applic. Date: 2000-06-30; WO2000US08718 Applic. Date: 2000-04-11

Inventor: BLASETTI LOU [US]; KEVY SHERWIN V [US]


Application No.: US20130240361A1  Published: 19/Sep/2013

Title: ELECTROSORPTION AND DECOMPOSITION DEVICE FOR THE PURIFICATION OF BLOOD AND OTHER FLUIDS

Applicant/Assignee: ICINNOVATION BV

Application No.: 13/874884   Filing Date: 01/May/2013

Abstract:

A device for the removal of toxic substances from biofluids has an electrocatalytic decomposition filter positioned between an inlet and an outlet. The filter includes a DC power source, a set of electrodes with a catalytic surface or in direct contact with sorbents offering catalytic activity, and an electrosorption filter for removing toxic substances.

Priority: EP20100189728 Applic. Date: 2010-11-02; EP20110161646 Applic. Date: 2011-04-08; WO2011NL50746 Applic. Date: 2011-11-02

Inventor: SIMONIS FRANK [NL]


Application No.: US20130240422A1  Published: 19/Sep/2013

Title: System and Method For Plasma Reduced Platelet Collection

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 13/875763   Filing Date: 02/May/2013

Abstract:

A method and apparatus for collecting plasma reduced platelets potentially suspended in a synthetic solution from a donor. Whole blood is drawn from the donor and introduced into a separation chamber. Platelets are extracted from the separation chamber into a container, using, for example, surge (with anticoagulated plasma or a synthetic solution) or push methodologies. The remaining blood components in the separation chamber are returned back to the donor. The steps of drawing whole blood and introducing the whole blood into the separation chamber, extracting platelets from the separation chamber into the container, and returning the remaining components in the chamber back to the donor are repeated. The sequestered platelets in the container are reintroduced into the separation chamber, whereupon a plasma reduced platelet product is extracted.

Priority: US2008-102486 Applic. Date: 2008-04-14

Inventor: OHASHI TOSHIYASU [JP]; PAGES ETIENNE [FR]; UHLMANN DOMINIQUE [US]; MAILLARD PASCAL [CH]; RAGUSA MICHAEL [US]


Application No.: US20130253417A1  Published: 26/Sep/2013

Title: Distal Access Balloon Guide Catheter

Applicant/Assignee:

Application No.: 13/623941   Filing Date: 21/Sep/2012

Abstract:

Distal access balloon guide catheter system and methods for delivering implantable devices, catheters, or substances in or near and/or restoring flow through body lumens, such as blood vessel lumens, or inflating balloons affixed to the distal end of the guide catheter system are described. A Distal access balloon guide catheter having a proximal region, an optional medial region of intermediate flexibility, and distal region possessing high flexibility, high resistance to kinking and a large lumen to wall thickness ratio. The balloon is inflated by means of a kink-resistant secondary lumen embedded within the walls of the balloon guide catheter system tubing.

Priority: US201161538719P Applic. Date: 2011-09-23

Inventor: DINH JAMES [US]; CASTENADA MARICRUZ [US]; SHIMADA LYNN MIYEKO [US]; TORRES SEFERINO ENRIQUE [US]; STRAUSS BRIAN MICHAEL [US]; VALKO JEFFREY J [US]


Application No.: US20130261529A1  Published: 03/Oct/2013

Title: EXTRACORPOREAL BLOOD TREATMENT AND SYSTEM HAVING REVERSIBLE BLOOD PUMPS

Applicant/Assignee: GAMBRO UF SOLUTIONS, INC

Application No.: 13/904358   Filing Date: 29/May/2013

Abstract:

An extracorporeal blood processing method using a blood circuit comprising a pair of blood passages attached to opposite flow ends of a blood treatment device and said blood circuit is mounted on a blood pump console, the method includes: withdrawing blood from a vascular system of a human patient and drawing the blood into the blood circuit

pumping the withdrawn blood through one of the pair of blood passages using a first blood pump of the console and into the blood treatment device

pumping the treated blood from the treatment device through the other of the pair of blood passages using a second blood pump of the console

infusing the treated blood from the other blood passage and into the vascular system of the patient, and periodically reversing a flow direction of blood through the pair of blood passages and blood treatment device.

Priority: US2009-613588 Applic. Date: 2009-11-06; US2004-002442 Applic. Date: 2004-12-03

Inventor: O'MAHONY JOHN [US]


Application No.: US20130261597A1  Published: 03/Oct/2013

Title: Therapeutic Material Delivery System for Tissue Voids and Cannulated Implants

Applicant/Assignee: BIOACTIVE SURGICAL, INC

Application No.: 13/588110   Filing Date: 17/Aug/2012

Abstract:

Described herein is a novel drug delivery assembly having particular applicability to the field of orthopedic and surgical medicine. The devices and assemblies described herein enable the efficient application and retention of potentially expensive therapeutic materials to very specific locations, particularly those associated with voids in bone and tissue. One particularly unique aspect of the present invention involves the introduction of constructs which promote the retention of therapeutic material in the target area of application for beneficial use, for example by forming a proximal barrier that prevents leakage of the therapeutic material out of the target area. Additionally, the present invention provides unique devices and methods for surgical introduction of such constructs. The present invention finds particular application in connection with introduction of stem and progenitor cells, bioactive molecules and bone scaffold materials in conjunction with bone voids and with the use of cannulated implants, such as bone screws (also surgical screws) and pins. The present invention also has beneficial use in the delivery of cancer drugs, antimicrobials, bone cements and other therapeutic materials.

Priority: US2009-414194 Applic. Date: 2009-03-30; US2008-116465P Applic. Date: 2008-11-20; US2009-154718P Applic. Date: 2009-02-23

Inventor: SPEDDEN RICHARD H [US]; SCHON LEW C [US]; PINGEL LAURA J [US]


Application No.: US20130266560A1  Published: 10/Oct/2013

Title: Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Applicant/Assignee:

Application No.: 13/830831   Filing Date: 14/Mar/2013

Abstract:

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Priority: US201213441827 Applic. Date: 2012-04-06; US201161473698P Applic. Date: 2011-04-08

Inventor: DEMOPULOS GREGORY A [US]; DUDLER THOMAS [US]; SCHWAEBLE HANS-WILHELM [GB]


Application No.: US20130267584A1  Published: 10/Oct/2013

Title: APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/797414   Filing Date: 12/Mar/2013

Abstract:

The present invention provides compositions and methods for modulating TFPI protein plasma concentration and TFPI protein function. Such modulation can be used to treat blood disorders such as bleeding disorders and clotting disorders.

Priority: US201261614438P Applic. Date: 2012-03-22; US201261667823P Applic. Date: 2012-07-03

Inventor: DOCKAL MICHAEL [AT]; SCHEIFLINGER FRIEDRICH [AT]


Application No.: US20130273576A1  Published: 17/Oct/2013

Title: REAGENTS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee:

Application No.: 13/862632   Filing Date: 15/Apr/2013

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.

Priority: US2010-771634 Applic. Date: 2010-04-30

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]; OMAKOR JOHN EMEGBERO [CA]; MOSS ADAM ROGER [CA]; GUHADOS GANESH [CA]


Application No.: US20130274195A1  Published: 17/Oct/2013

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF

Applicant/Assignee: CELERA CORPORATION, ON BEHALF OF ACADEMIC HOSPITAL LEIDEN LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) ACTING

Application No.: 13/726344   Filing Date: 24/Dec/2012

Abstract:

The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Priority: US201113270936 Applic. Date: 2011-10-11; US2009-403552 Applic. Date: 2009-03-13; US2008-069687P Applic. Date: 2008-03-13

Inventor: BARE LANCE [US]; DEVLIN JAMES J [US]; ROSENDAAL FRITS R [NL]; REITSMA PIETER H [NL]; BEZEMER IRENE D [NL]


Application No.: US20130280334A1  Published: 24/Oct/2013

Title: Nanostructured Gels Capable of Controlled Release of Encapsulated Agents

Applicant/Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC

Application No.: 13/825486   Filing Date: 23/Sep/2011

Abstract:

Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described.

Priority: US2010-386268P Applic. Date: 2010-09-24; US201161466753P Applic. Date: 2011-03-23; WO2011US53075 Applic. Date: 2011-09-23

Inventor: KARP JEFFREY M [US]; VEMULA PRAVEEN KUMAR [US]; CAMPBELL NATHANIEL R [US]; SYED ABDULLAH M [CA]; ZHANG SUFENG [US]; FAROKHZAD OMID C [US]; LANGER ROBERT S [US]


Application No.: US20130280342A1  Published: 24/Oct/2013

Title: System and Method for Collecting Platelets and Anticipating Plasma Return

Applicant/Assignee:

Application No.: 13/922572   Filing Date: 20/Jun/2013

Abstract:

A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and sends the first blood component to a first blood component bag. The first return line fluidly connects the venous-access device and the blood component separation device. The recirculation line connects the first blood component container and the separation device. The second return line fluidly connects the first blood component container and the first return line and is configured to return the first blood component within the first blood container to the subject.

Priority: WO2010US62540 Applic. Date: 2010-12-30

Inventor: PAGES ETIENNE [FR]


Application No.: US20130280693A1  Published: 24/Oct/2013

Title: DENSITY-BASED SEPARATION OF BIOLOGICAL ANALYTES USING MULTIPHASE SYSTEMS

Applicant/Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE A UNIVERSITY

Application No.: 13/817985   Filing Date: 22/Aug/2011

Abstract:

The disclosed methods use a multi-phase system to separate samples according to the density of an analyte of interest. The method uses a multi-phase system that comprises two or more phase-separated solutions and a phase component such as a surfactant or polymer. The density of the analyte of interest differs from the densities of the rest of the sample. The density of the analyte of interest is substantially the same as one or more phases. Thus, when the sample is introduced to the multi-phase system, the analyte of interest migrates to the phase having the same density as the analyte of interest, passing through one or more phases sequentially.

Priority: US2010-375532P Applic. Date: 2010-08-20; WO2011US48678 Applic. Date: 2011-08-22

Inventor: MACE CHARLES R [US]; KUMAR ASHOK A [US]; WIRTH DYANN F [US]; WHITESIDES GEORGE M [US]


Application No.: US20130287728A1  Published: 31/Oct/2013

Title: Compositions and Methods for Treating Progressive Myocardial Injury Due to A Vascular Insufficiency

Applicant/Assignee:

Application No.: 13/795968   Filing Date: 12/Mar/2013

Abstract:

The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion

and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events.

Priority: US201113285606 Applic. Date: 2011-10-31

Inventor: PECORA ANDREW L [US]; PRETI ROBERT A [US]


Application No.: US20130289702A1  Published: 31/Oct/2013

Title: STENT-GRAFT PROSTHESIS FOR PLACEMENT IN THE ABDOMINAL AORTA

Applicant/Assignee: MEDTRONIC VASCULAR, INC

Application No.: 13/458242   Filing Date: 27/Apr/2012

Abstract:

A self-expanding main vessel stent-graft includes a trunk portion configured for placement within the abdominal aorta and a bifurcated portion configured for placement above the aortic bifurcation of the common iliac arteries. The trunk portion includes a proximal end section having an anchor stent and a seal stent that accommodates a scallop or open-top fenestration

a suprarenal body section having at least one stent of variable stiffness to accommodate branch vessel prosthesis deployed alongside the main vessel stent-graft

a branch connection section having opposing couplings for connecting the main vessel stent-graft to branch vessel prostheses deployed within the renal arteries

an infrarenal body section having at least one stent of uniform stiffness

and a transition section for transitioning into the bifurcated portion. The main vessel stent-graft is configured to treat short-neck infrarenal, juxtarenal, and/or suprarenal aneurysms in a wide range of patient anatomies.

Priority:

Inventor: COGHLAN KIERAN [US]; SIMMONS EMILIE [US]; PEARSON MEGHAN [US]


Application No.: US20130296828A1  Published: 07/Nov/2013

Title: THERAPEUTIC MATERIAL DELIVERY SYSTEM FOR TISSUE VOIDS AND CANNULATED IMPLANTS

Applicant/Assignee: BIOACTIVE SURGICAL, INC

Application No.: 13/935819   Filing Date: 05/Jul/2013

Abstract:

Described herein is a novel drug delivery assembly having particular applicability to the field of orthopedic and surgical medicine. The devices and assemblies described herein enable the efficient application and retention of potentially expensive therapeutic materials to very specific locations, particularly those associated with voids in bone and tissue. One particularly unique aspect of the present invention involves the introduction of constructs which promote the retention of therapeutic material in the target area of application for beneficial use, for example by forming a proximal barrier that prevents leakage of the therapeutic material out of the target area. Additionally, the present invention provides unique devices and methods for surgical introduction of such constructs. The present invention finds particular application in connection with introduction of stem and progenitor cells, bioactive molecules and bone scaffold materials in conjunction with bone voids and with the use of cannulated implants, such as bone screws (also surgical screws) and pins. The present invention also has beneficial use in the delivery of cancer drugs, antimicrobials, bone cements and other therapeutic materials.

Priority: US201213588110 Applic. Date: 2012-08-17; US2009-414194 Applic. Date: 2009-03-30; US2008-116465P Applic. Date: 2008-11-20; US2009-154718P Applic. Date: 2009-02-23

Inventor: SCHON LEW C [US]; SPEDDEN RICHARD H [US]; PINGEL LAURA J [US]


Application No.: US20130302399A1  Published: 14/Nov/2013

Title: ANTI-PCSK9 ANTIBODIES AND USE THEREOF

Applicant/Assignee:

Application No.: 13/795674   Filing Date: 12/Mar/2013

Abstract:

The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.

Priority: US201261644065P Applic. Date: 2012-05-08; US201261654481P Applic. Date: 2012-06-01

Inventor: FELDHAUS ANDREW LAWRENCE [US]; GARCIA-MARTINEZ LEON F [US]; DUTZAR BENJAMIN H [US]; OJALA ETHAN WAYNE [US]; KOVACEVICH BRIAN ROBERT [US]; OLSON KATIE [US]; FAN PEI [US]; BILLGREN JENS [US]; STEWART ERICA ANN [US]; AKATSUKA CORINNE C [US]; MCNEILL PATRICIA DIANNE [US]; MITCHELL DANIELLE MARIE [US]; ALLISON DAN SCOTT [US]; LATHAM JOHN A [US]


Application No.: US20130303462A1  Published: 14/Nov/2013

Title: USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/892529   Filing Date: 13/May/2013

Abstract:

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

Priority: EP20120167953 Applic. Date: 2012-05-14; EP20120170888 Applic. Date: 2012-06-05; EP20120006812 Applic. Date: 2012-09-28; EP20120190447 Applic. Date: 2012-10-29

Inventor: KLEIN THOMAS [DE]; VON EYNATTEN MAXIMILIAN [DE]; HOCHER BERTHOLD [DE]; MARK MICHAEL [DE]; SHARKOVSKA YULIYA [DE]


Application No.: US20130304020A1  Published: 14/Nov/2013

Title: BLOOD TREATMENT SYSTEMS AND METHODS

Applicant/Assignee: DEKA PRODUCTS LIMITED PARTNERSHIP

Application No.: 13/855620   Filing Date: 02/Apr/2013

Abstract:

Dialysis systems comprising actuators that cooperate to perform dialysis functions and sensors that cooperate to monitor dialysis functions are disclosed. According to one aspect, such a hemodialysis system comprises a user interface model layer, a therapy layer, below the user interface model layer, and a machine layer below the therapy layer. The user interface model layer is configured to manage the state of a graphical user interface and receive inputs from a graphical user interface. The therapy layer is configured to run state machines that generate therapy commands based at least in part on the inputs from the graphical user interface. The machine layer is configured to provide commands for the actuators based on the therapy commands.

Priority: US2009-549285 Applic. Date: 2009-08-27; US2008-199452 Applic. Date: 2008-08-27; US2008-072908 Applic. Date: 2008-02-27; US2007-903582P Applic. Date: 2007-02-27; US2007-904024P Applic. Date: 2007-02-27; US2008-092239P Applic. Date: 2008-08-27

Inventor: WILT MICHAEL J [US]; BALLANTYNE TODD A [US]; DEMERS JASON A [US]


Application No.: US20130304166A1  Published: 14/Nov/2013

Title: INHIBITION OF PLATELET ACTIVATION, AGGREGATION AND/OR ADHESION BY HYPOTHERMIA

Applicant/Assignee: ZOLL CIRCULATION INC

Application No.: 13/868764   Filing Date: 23/Apr/2013

Abstract:

A method for treating acute coronary syndromes (i.e., unstable angina or non-Q-wave MI) or transient ischemic attacks in a human or animal patient by placing a heat exchange apparatus in the patient's vasculature and using that heat exchange apparatus to cool the patient to a temperature (e.g. 30-36 degrees C.) at which platelet inhibition (i.e., inhibition of platelet activation and/or aggregation and/or adhesion) occurs. Anti-shivering drugs or anesthesia may be administered to patients whose body temperature is cooled below that patient's shivering threshold (typically approximately 35.5 degrees C.). If it is determined that platelet inhibition is no longer desirable, such as when the patient is about to undergo a surgical or interventional procedure wherein bleeding could be problematic, the hypothermia-induced platelet inhibition may be rapidly reversed by using the intravascular heat exchange apparatus to re-warm the patient's body to normothermia or near normothermia.

Priority: US2010-962487 Applic. Date: 2010-12-07; US2006-501442 Applic. Date: 2006-08-08; US2003-408617 Applic. Date: 2003-04-07; US2001-790249 Applic. Date: 2001-02-21

Inventor: DAE MICHAEL W [US]; MACHOLD TIMOTHY R [US]; KELLER WADE A [US]


Application No.: US20130310340A1  Published: 21/Nov/2013

Title: METHOD OF TREATING MUSCULAR DEGRADATION

Applicant/Assignee: RIGEL PHARMACEUTICALS, INC

Application No.: 13/895152   Filing Date: 15/May/2013

Abstract:

A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such as may result from ventilation.

Priority: US201261647982P Applic. Date: 2012-05-16

Inventor: PAYAN DONALD G [US]; MASUDA ESTEBAN [US]; KINSELLA TODD [US]


Application No.: US20130313194A1  Published: 28/Nov/2013

Title: METHOD OF OPTIMIZING CLEARANCE FOR PROTEIN-BOUND MOLECULES USING CASCADE FILTRATION THERAPY

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/959087   Filing Date: 05/Aug/2013

Abstract:

A method of removing unwanted molecules from blood includes (i) directing a flow of blood from a patient through a first hemofilter, (ii) removing a volume of fluid from the blood using the first hemofilter, (iii) combining a volume of first substitution fluid with an outflow from the first hemofilter, the volume of first substitution fluid being substantially equal to the volume of fluid removed from the blood using the first hemofilter, (iv) directing the combined first hemofilter outflow and the first substitution fluid volume from the first hemofilter through a second hemofilter, (v) combining a second substitution fluid with outflow from the second hemofilter, and (vi) returning the combined second hemofilter outflow and the second substitution fluid volume from the second hemofilter to the patient.

Priority: US2008-252219 Applic. Date: 2008-10-15; US2007-982396P Applic. Date: 2007-10-24

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20130315897A1  Published: 28/Nov/2013

Title: Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 13/889982   Filing Date: 08/May/2013

Abstract:

The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Priority: US201113213912 Applic. Date: 2011-08-19; US2008-101644 Applic. Date: 2008-04-11; US2007-911852P Applic. Date: 2007-04-13

Inventor: SINHA UMA [US]; HOLLENBACH STANLEY J [US]; ANDRE PATRICK [US]


Application No.: US20130316011A1  Published: 28/Nov/2013

Title: Expanded Utility of Red Cell-Derived Microparticles (RMP) for Treatment of Bleeding

Applicant/Assignee: UNIVERSITY OF MIAMI

Application No.: 13/982224   Filing Date: 27/Jan/2012

Abstract:

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired. Administration of RMP prepared according to the invention demonstrates effectiveness in safely reducing bleeding.

Priority: US201161457203P Applic. Date: 2011-01-28; WO2012US23020 Applic. Date: 2012-01-27

Inventor: AHN YEON S [US]; HORSTMAN LAWRENCE L [US]; JY WENCHE [US]


Application No.: US20130323122A1  Published: 05/Dec/2013

Title: CITRATE ANTICOAGULATION SYSTEM FOR EXTRACORPOREAL BLOOD TREATMENTS

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/960234   Filing Date: 06/Aug/2013

Abstract:

A machine-readable medium with instructions for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Priority: EP19990201302 Applic. Date: 1999-04-26; US201213359109 Applic. Date: 2012-01-26; US2006-602827 Applic. Date: 2006-11-21; US2003-742137 Applic. Date: 2003-12-19; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20; US2005-739086P Applic. Date: 2005-11-22

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20130324897A1  Published: 05/Dec/2013

Title: SPRAY FOAM SPLINT

Applicant/Assignee: USA, AS REPRESENTED BY THE SECRETARY OF THE ARMY

Application No.: 13/988260   Filing Date: 18/Nov/2010

Abstract:

Orthopedic splinting materials and methods for stabilizing an injured limb or extremity of a human or animal comprising applying a foam to the limb or extremity and allowing the foam set to sufficient rigidity, which can be in less than 60 seconds. The foam, such as a Spray Polyurethane Foam, can be sprayed directly on the skin without producing an amount of heat release that is painful or uncomfortable on the skin. Also provided is a kit for stabilizing an injured limb or extremity comprising a dispenser comprising the present foam. Further provided is situ preparation and application of a compression bandage on an injured patient in an emergency or combat situation comprising applying the present foam. A spine board and a method for making the same comprising applying the present foam to the patient's back, then contacting the foam with a board or flat surface before the foam sets.

Priority: WO2010US57240 Applic. Date: 2010-11-18

Inventor: MARTIN KEVIN D [US]


Application No.: US20130330841A1  Published: 12/Dec/2013

Title: METHOD FOR MEASURING CARDIAC TROPONIN

Applicant/Assignee: MITSUBISHI CHEMICAL MEDIENCE CORPORATION

Application No.: 14/001159   Filing Date: 24/Feb/2012

Abstract:

Disclosed are a method for immunologically measuring cardiac troponin in a biological sample, in which the formation of an immunological complex of cardiac troponin with an antibody specifically binding thereto is performed in the presence of a divalent cation at 4 mmol/L or more

and a kit for measuring cardiac troponin, comprising an antibody specifically binding to cardiac troponin, and a buffer containing a divalent cation at a high concentration. According to the method or the kit, a stable and highly-accurate measured value can be obtained without being affected by interfering substances in a specimen regardless of the type of specimen.

Priority: WO2012JP54541 Applic. Date: 2012-02-24; JP20110039625 Applic. Date: 2011-02-25

Inventor: OKAMURA YOSHIKAZU [JP]


Application No.: US20130331815A1  Published: 12/Dec/2013

Title: METHOD AND APPARATUS FOR CONTROLLING THE FLOW RATE OF WASHING SOLUTION DURING THE WASHING STEP IN A BLOOD CENTRIFUGATION BOWL

Applicant/Assignee: SORIN GROUP ITALIA S.R.L

Application No.: 13/963960   Filing Date: 09/Aug/2013

Abstract:

A method of washing blood mixed with undesirable elements not normally found in healthy whole blood to remove the undesirable elements, the method comprising: separating the blood into components according to relative densities of the components with a rotating centrifuge bowl

providing a port through which fluid exits the bowl, the exiting fluid having a concentration of undesirable elements

flowing washing solution into the centrifuge bowl at an initial flow rate

monitoring the fluid exiting the bowl with an optical sensor having an output signal indicative of the composition of the exiting fluid

and increasing and decreasing the flow rate of the wash solution as a function of the output signal.

Priority: US2006-604664 Applic. Date: 2006-11-27

Inventor: FORTINI MATTEO [IT]; REGGIANI STEFANO [IT]; PANZANI IVO [IT]


Application No.: US20130344519A1  Published: 26/Dec/2013

Title: METHODS AND SYSTEMS FOR ASSESSMENT OF TURBIDITY KINETICS (WAVEFORM ANALYSIS) IN COAGULATION TESTING

Applicant/Assignee: BAYER HEALTHCARE LLC

Application No.: 13/926966   Filing Date: 25/Jun/2013

Abstract:

In some embodiments, a method is provided that includes (1) obtaining a plasma sample from a patient

(2) performing a coagulation assay on the plasma sample

(3) measuring a coagulation property of the plasma sample using a coagulation analyzer so as to generate measured data

(3) performing waveform analysis on the measured data so as to obtain turbidity characteristics

and (4) employing the waveform analysis to determine a coagulation status of the coagulation assay not provided by the coagulation analyzer. Numerous other embodiments are provided.

Priority: US201261663912P Applic. Date: 2012-06-25; US201361793864P Applic. Date: 2013-03-15

Inventor: LEONG LILLEY [US]; RAMSEY PHILIP [US]


Application No.: US20130345262A1  Published: 26/Dec/2013

Title: METHOD FOR PREVENTION OF STROKE

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/923762   Filing Date: 21/Jun/2013

Abstract:

A method for administering Dabigatran, optionally in the form of a pharmaceutically acceptable salt thereof, to a patient in need of an anticoagulant and/or antithrombotic medicament wherein the daily dose is determined by the dosage regimen including one measurement of dabigatran plasma level.

Priority: EP20120173398 Applic. Date: 2012-06-25

Inventor: DUGI KLAUS [DE]; CLEMENS ANDREAS [DE]; LEHR THORSTEN [DE]; NOACK HERBERT [DE]


Application No.: US20130345314A1  Published: 26/Dec/2013

Title: Compositions and methods for treating a damaged cardiovascular element

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 13/974903   Filing Date: 23/Aug/2013

Abstract:

In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset.

Priority: US2006-443594 Applic. Date: 2006-05-31; US2005-685831P Applic. Date: 2005-05-31

Inventor: ROY JOSEE [US]; AYALA HEZI-YAMIT [US]; SULLIVAN CAROL [US]; CHEN MINGFEI [US]


Application No.: US20130345674A1  Published: 26/Dec/2013

Title: MEMBRANE SEPARATION DEVICES, SYSTEMS AND METHODS EMPLOYING SAME, AND DATA MANAGEMENT SYSTEMS AND METHODS

Applicant/Assignee: FENWAL, INC

Application No.: 14/003284   Filing Date: 09/Mar/2012

Abstract:

A membrane separation device is disclosed along with systems and methods employing the device in blood processing procedures. In one embodiment, a spinning membrane separator is provided in which at least two zones or regions are created in the gap between the membrane and the shell, such that mixing of the fluid between the two regions is inhibited by a radial rib associated with the membrane that decreases the gap between the membrane and the shell to define two fluid regions, the ridge isolating the fluid in the two regions to minimize mixing between the two. Automated systems and methods are disclosed for separating a unit of previously collected whole blood into components, such as concentrated red cells and plasma, for collecting red cells and plasma directly from a donor in a single pass, and for cell washing. Data management systems and methods and priming methods are also disclosed.

Priority: US201161451903P Applic. Date: 2011-03-11; US201161537856P Applic. Date: 2011-09-22; US201161538558P Applic. Date: 2011-09-23; US201161550516P Applic. Date: 2011-10-24; WO2012US28512 Applic. Date: 2012-03-09

Inventor: KUSTERS BENJAMIN E [US]; WEGENER CHRISTOPHER J [US]; BOGGS DANIEL R [US]; MIN KYUNGYOON [US]; CORK WILLIAM H [US]; CALHOUN DARYL R [US]; BLICKHAN BRYAN [US]; LYNN DANIEL [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
 
US Patent Applications published in 2012
Provisional Patents in Blood Anticlot Technology, Medications and
Medical Devices Published in 2013